BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang CY, Hsieh FS, Wang CY, Chen LJ, Chang SS, Tsai MH, Hung MH, Kuo CW, Shih CT, Chao TI, Chen KF. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer 2018;102:10-22. [PMID: 30103095 DOI: 10.1016/j.ejca.2018.07.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Jost T, Heinzerling L, Fietkau R, Hecht M, Distel LV. Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation. Front Oncol 2021;11:740002. [PMID: 34722291 DOI: 10.3389/fonc.2021.740002] [Reference Citation Analysis]
2 Mirza-aghazadeh-attari M, Mohammadzadeh A, Yousefi B, Mihanfar A, Karimian A, Majidinia M. 53BP1: A key player of DNA damage response with critical functions in cancer. DNA Repair 2019;73:110-9. [DOI: 10.1016/j.dnarep.2018.11.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
3 Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5232. [PMID: 32718047 DOI: 10.3390/ijms21155232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Petroni G, Cantley LC, Santambrogio L, Formenti SC, Galluzzi L. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nat Rev Clin Oncol 2021. [PMID: 34819622 DOI: 10.1038/s41571-021-00579-w] [Reference Citation Analysis]
5 Göttgens EL, Bussink J, Leszczynska KB, Peters H, Span PN, Hammond EM. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys 2019;105:548-58. [PMID: 31271827 DOI: 10.1016/j.ijrobp.2019.06.2531] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
6 Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. Innovation (N Y) 2020;1:100032. [PMID: 32914142 DOI: 10.1016/j.xinn.2020.100032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
7 Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh MA, Wang D, Patel KR, Barry PN, Rao RD. Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination. Adv Radiat Oncol 2019;4:453-7. [PMID: 31360799 DOI: 10.1016/j.adro.2019.03.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
8 van Aken ESM, Beeker A, Houtenbos I, Pos FJ, Linn SC, Elkhuizen PHM, de Jong MC. Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy. Cancer Rep (Hoboken) 2021;:e1470. [PMID: 34145976 DOI: 10.1002/cnr2.1470] [Reference Citation Analysis]
9 Edwards DM, Speers C, Wahl DR. Targeting Noncanonical Regulators of the DNA Damage Response to Selectively Overcome Cancer Radiation Resistance. Semin Radiat Oncol 2022;32:64-75. [PMID: 34861997 DOI: 10.1016/j.semradonc.2021.09.006] [Reference Citation Analysis]
10 Russo LC, Farias JO, Forti FL. DUSP3 maintains genomic stability and cell proliferation by modulating NER pathway and cell cycle regulatory proteins. Cell Cycle 2020;19:1545-61. [PMID: 32380926 DOI: 10.1080/15384101.2020.1762043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A, Wong KK. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Ther Adv Med Oncol 2018;10:1758835918808509. [PMID: 30542378 DOI: 10.1177/1758835918808509] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
12 Fernández-Aroca DM, Roche O, Sabater S, Pascual-Serra R, Ortega-Muelas M, Sánchez Pérez I, Belandia B, Ruiz-Hidalgo MJ, Sánchez-Prieto R. P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy. Cancer Lett 2019;451:23-33. [PMID: 30872077 DOI: 10.1016/j.canlet.2019.02.049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
13 Lee J, Park HS, Won HS, Yang JH, Lee HY, Woo IS, Shin K, Hong JH, Yang YJ, Chun SH, Byun JH. Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions. Cancer Res Treat 2021;53:409-23. [PMID: 33138346 DOI: 10.4143/crt.2020.451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Gil-Gil M, Alba E, Gavilá J, de la Haba-Rodríguez J, Ciruelos E, Tolosa P, Candini D, Llombart-Cussac A. The role of CDK4/6 inhibitors in early breast cancer. Breast 2021;58:160-9. [PMID: 34087775 DOI: 10.1016/j.breast.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zhang J, Xu D, Zhou Y, Zhu Z, Yang X. Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC. Front Oncol 2021;11:676041. [PMID: 34395246 DOI: 10.3389/fonc.2021.676041] [Reference Citation Analysis]
16 Meattini I, Livi L, Lorito N, Becherini C, Bacci M, Visani L, Fozza A, Belgioia L, Loi M, Mangoni M, Lambertini M, Morandi A. Integrating radiation therapy with targeted treatments for breast cancer: from bench to bedside. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102417] [Reference Citation Analysis]
17 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Sad K, Parashar P, Tripathi P, Hungyo H, Sistla R, Soni R, Tandon V. Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Free Radic Biol Med 2021;177:299-312. [PMID: 34742922 DOI: 10.1016/j.freeradbiomed.2021.11.001] [Reference Citation Analysis]
19 de Almeida LC, Calil FA, Machado-neto JA, Costa-lotufo LV. DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. Cancer Genetics 2021;252-253:6-24. [DOI: 10.1016/j.cancergen.2020.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Bosacki C, Bouleftour W, Sotton S, Vallard A, Daguenet E, Ouaz H, Cojoracu I, Moslemi D, Molekzadehmoghani M, Magné N. CDK 4/6 inhibitors combined with radiotherapy: A review of literature. Clin Transl Radiat Oncol 2021;26:79-85. [PMID: 33319074 DOI: 10.1016/j.ctro.2020.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Xue L, Guo C, Zhang K, Jiang H, Pang F, Dou Y, Liu X, Lin H, Dong X, Zhao S, Yao M, Wang K, Feng Y, Gu W. Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. Hepatobiliary Surg Nutr 2019;8:615-22. [PMID: 31929988 DOI: 10.21037/hbsn.2019.08.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
22 Chen C, Nelson LJ, Ávila MA, Cubero FJ. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells 2019;8:E1172. [PMID: 31569444 DOI: 10.3390/cells8101172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
23 Horbinski C, Xi G, Wang Y, Hashizume R, Gopalakrishnan M, Phillips JJ, Houghton P, James CD, Kalapurakal JA. The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. Neurooncol Adv 2021;3:vdab085. [PMID: 34345820 DOI: 10.1093/noajnl/vdab085] [Reference Citation Analysis]
24 Gillman R, Lopes Floro K, Wankell M, Hebbard L. The role of DNA damage and repair in liver cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188493. [PMID: 33316376 DOI: 10.1016/j.bbcan.2020.188493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Yang Y, Luo J, Chen X, Yang Z, Mei X, Ma J, Zhang Z, Guo X, Yu X. CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. J Exp Clin Cancer Res 2020;39:188. [PMID: 32933570 DOI: 10.1186/s13046-020-01693-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Saengboonmee C, Detarya M, Sangkhamanon S, Sawanyawisuth K, Seubwai W, Wongkham S. High Glucose Induced Upregulation of Cyclin a Associating with a Short Survival of Patients with Cholangiocarcinoma: A Potential Target for Treatment of Patients with Diabetes Mellitus. Nutr Cancer 2021;:1-11. [PMID: 34353198 DOI: 10.1080/01635581.2021.1961830] [Reference Citation Analysis]
27 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Sager RA, Dushukyan N, Woodford M, Mollapour M. Structure and function of the co-chaperone protein phosphatase 5 in cancer. Cell Stress Chaperones 2020;25:383-94. [PMID: 32239474 DOI: 10.1007/s12192-020-01091-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
29 Barberi V, Pietragalla A, Franceschini G, Marazzi F, Paris I, Cognetti F, Masetti R, Scambia G, Fabi A. Oligometastatic Breast Cancer: How to Manage It? J Pers Med 2021;11:532. [PMID: 34207648 DOI: 10.3390/jpm11060532] [Reference Citation Analysis]
30 Reinius MAV, Smyth E. Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. Expert Rev Mol Med 2021;23:e6. [PMID: 34103115 DOI: 10.1017/erm.2021.3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Nia A, Dhanasekaran R. Genomic Landscape of HCC. Curr Hepatol Rep 2020;19:448-61. [PMID: 33816052 DOI: 10.1007/s11901-020-00553-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
33 Guerini AE, Pedretti S, Salah E, Simoncini EL, Maddalo M, Pegurri L, Pedersini R, Vassalli L, Pasinetti N, Peretto G, Triggiani L, Costantino G, Figlia V, Alongi F, Magrini SM, Buglione M. A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Sci Rep 2020;10:13589. [PMID: 32788596 DOI: 10.1038/s41598-020-70430-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
34 Campbell A, Gutierrez DA, Knight C, Vines CM, Heydarian R, Philipovskiy A, Varela-Ramirez A, Boland T. Novel Combinatorial Strategy Using Thermal Inkjet Bioprinting, Chemotherapy, and Radiation on Human Breast Cancer Cells; an In-Vitro Cell Viability Assessment. Materials (Basel) 2021;14:7864. [PMID: 34947458 DOI: 10.3390/ma14247864] [Reference Citation Analysis]